Evidence map›Paper›PMID 26970137›Full record

ReviewSeminars in oncology2016

The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Robert H Shoemaker, Chen S Suen, Cathy A Holmes, Judith R Fay, Vernon E Steele

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Robert H ShoemakerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: Shoemakr@mail.nih.gov.
Chen S SuenChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cathy A HolmesCCS Associates, Inc, Mountain View, CA, USA.
Judith R FayCCS Associates, Inc, Mountain View, CA, USA.
Vernon E SteeleChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

Intramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261201200013CNCI NIH HHS HHSN261201200013INCI NIH HHS HHSN261201200015CNCI NIH HHS HHSN261201200021CNCI NIH HHS HHSN261201200021I
6 · The paper itself

Abstract

The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a National Cancer Institute, Division of Cancer Prevention (NCI, DCP)-supported program whose primary goal is to bring new cancer preventive interventions (small molecules and vaccines) and biomarkers through preclinical development towards clinical trials by creating partnerships between the public sector (eg, academia, industry) and DCP. PREVENT has a formalized structure for moving interventions forward in the prevention pipeline using a stage-gate process with go/no go decision points along the critical path for development. This review describes the structure of the program, its focus areas, and provides examples of projects currently in the pipeline.

Indexed as

Anticarcinogenic AgentsCancer VaccinesDrug DiscoveryNational Cancer Institute (U.S.)AnimalsChemopreventionDisease Models, AnimalGovernment ProgramsHumansMolecular Targeted TherapyNeoplasmsTranslational Research, BiomedicalUnited StatesAnticarcinogenic AgentsCancer VaccinesCancerChemopreventionImmunopreventionPreclinical support

Identifiers

PMID26970137
PMCPMC4789768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.